Type I anti-CD20 monoclonal antibody mediating complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis.
Chimeric type I anti-CD20 monoclonal antibody that binds CD20 on B cells and induces cell death via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis, depleting CD20-positive B cells.
Rituximab binds CD20 on B cells and induces cell death via complement-dependent cytotoxicity, Fc-mediated ADCC by immune effector cells, and apoptosis.
Autologous, genetically engineered T cells expressing a chimeric antigen receptor that targets CD19 on B cells to mediate cytotoxicity in relapsed/refractory diffuse large B-cell lymphoma.
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor. CAR binding to CD19 on malignant and normal B cells triggers MHC-independent T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxicity, resulting in elimination of CD19-positive cells (e.g., in DLBCL).
Anti-CD19 CAR T cells bind CD19 and kill target cells via MHC-independent T-cell activation with perforin/granzyme-mediated cytotoxicity (and Fas–FasL apoptosis).
Oral small-molecule BH3-mimetic BCL-2 inhibitor (Venclexta) that induces apoptosis of BCL-2–dependent plasma cells; particularly relevant in t(11;14) AL amyloidosis where BCL-2 expression is high.
Selective BH3-mimetic BCL-2 inhibitor that binds the hydrophobic groove of BCL-2, blocks its anti-apoptotic function, and restores mitochondrial apoptosis in BCL-2–dependent tumor/plasma cells; does not inhibit BCL-XL, reducing thrombocytopenia risk.
Venetoclax is a BH3-mimetic that binds and inhibits BCL-2, displacing pro-apoptotic factors and enabling BAX/BAK activation, mitochondrial outer membrane permeabilization, caspase activation, and apoptosis in BCL-2–dependent cells.
Anti-CD38 IgGκ monoclonal antibody (Darzalex), administered subcutaneously; targets CD38 on clonal plasma cells and mediates ADCC, CDC, ADCP, and direct apoptosis.
Human IgG1κ monoclonal antibody against CD38 on clonal plasma cells; induces cell death via ADCC, CDC, ADCP, and direct apoptosis, and depletes CD38+ immunosuppressive cells.
Binds CD38 on target cells and induces NK cell–mediated ADCC via FcγR, complement-dependent cytotoxicity (CDC), macrophage phagocytosis (ADCP), and can trigger direct apoptosis upon crosslinking.
Afucosylated humanized IgG1 monoclonal antibody targeting CCR4; induces antibody-dependent cellular cytotoxicity against CCR4-positive malignant T cells and regulatory T cells.
Afucosylated humanized IgG1 monoclonal antibody targeting CCR4 (CD194) that blocks CCR4-mediated chemokine signaling/trafficking and induces enhanced FcγRIIIa-dependent ADCC, depleting CCR4-positive malignant T cells and regulatory T cells.
Anti-CCR4 IgG1 binds CCR4 on target cells and engages Fc-gamma RIIIa on NK/effector cells to trigger ADCC, leading to lysis/depletion of CCR4-positive malignant T cells and Tregs.